Matthew Edward Cove
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew Edward Cove has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
John A. Kellum
Department of Critical Care Medicine, Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, USA
5 shared publications- Christopher Yew Shuen Ang
School of Engineering, Monash University Malaysia, Selangor, Malaysia
3 shared publications Graeme MacLaren
Cardiothoracic ICU, National University Hospital, Singapore, Singapore
3 shared publications- James Geoffrey Chase
University of Canterbury
3 shared publications Jason Phua
Division of Respiratory and Critical Care Medicine, Department of Medicine National University Hospital Singapore Singapore
3 shared publicationsLien Hong Vu
Department of Medicine, National University Health System, Singapore
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 20 (6) , e70203
Practice and Perceptions on Extracorporeal Carbon Dioxide Removal in the Current Era: A Multinational Survey
Introduction: Extracorporeal carbon dioxide removal (ECCO 2 R) is a type of partial extracorporeal respiratory support with potential to reduce lung injury in patients with hypercapnic respiratory failure. We aimed to study the current practice and perceptions of ECCO 2 R and the need for an ECCO 2 R registry. Methods: A multinational survey was conducted among clinicians who have published clinical studies on ECCO 2 R or have used ECCO 2 R within the last 5 years in Europe, Asia, Oceania and the United States. Results: Seventy responses from 140 requests (response rate: 50%) were received from physicians across all targeted regions. ECCO 2 R is reported to be used mainly for ARDS (46%) management, followed by asthma (18%) and COPD (15%). Eighty‐five percent of the participants reported low case volumes (0–10 cases per year). Variations in the practice of ECCO 2 R were evident, including triggers for initiating ECCO 2 R, devices used, access catheter type and size, targeted blood flow rates and monitoring of anticoagulation. The most common barriers to wider use of ECCO 2 R included lack of evidence, followed by the device's costs and operational complexity. Eighty‐four percent (48/57) of the respondents thought an ECCO 2 R registry would be useful, and 98% (47/48) of the respondents reported that they would be willing to contribute to a dedicated ECCO 2 R registry. Conclusion: ECCO 2 R practices varied considerably, but most respondents agreed on the usefulness of a dedicated ECCO 2 R registry. Practice variations may be associated with suboptimal outcomes. ECCO 2 R quality indicators are needed to optimise clinical outcomes and resource utilisation.
- 16 June 2026
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 20 (6) , e70203
Open AccessPractice and Perceptions on Extracorporeal Carbon Dioxide Removal in the Current Era: A Multinational Survey
Introduction: Extracorporeal carbon dioxide removal (ECCO 2 R) is a type of partial extracorporeal respiratory support with potential to reduce lung injury in patients with hypercapnic respiratory failure. We aimed to study the current practice and perceptions of ECCO 2 R and the need for an ECCO 2 R registry. Methods: A multinational survey was conducted among clinicians who have published clinical studies on ECCO 2 R or have used ECCO 2 R within the last 5 years in Europe, Asia, Oceania and the United States. Results: Seventy responses from 140 requests (response rate: 50%) were received from physicians across all targeted regions. ECCO 2 R is reported to be used mainly for ARDS (46%) management, followed by asthma (18%) and COPD (15%). Eighty‐five percent of the participants reported low case volumes (0–10 cases per year). Variations in the practice of ECCO 2 R were evident, including triggers for initiating ECCO 2 R, devices used, access catheter type and size, targeted blood flow rates and monitoring of anticoagulation. The most common barriers to wider use of ECCO 2 R included lack of evidence, followed by the device's costs and operational complexity. Eighty‐four percent (48/57) of the respondents thought an ECCO 2 R registry would be useful, and 98% (47/48) of the respondents reported that they would be willing to contribute to a dedicated ECCO 2 R registry. Conclusion: ECCO 2 R practices varied considerably, but most respondents agreed on the usefulness of a dedicated ECCO 2 R registry. Practice variations may be associated with suboptimal outcomes. ECCO 2 R quality indicators are needed to optimise clinical outcomes and resource utilisation.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (7) , 1546-1562
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
Objective: To determine whether ivermectin improves outcomes for critically and noncritically ill hospitalized patients with COVID-19. Design: An ongoing international, multifactorial, adaptive platform, randomized, controlled trial. Setting: Hospitals in Pakistan, India, and Ireland between June 11, 2021, and September 9, 2022. Patients: Critically and noncritically ill patients. Interventions: Randomized to ivermectin or no ivermectin (control). Measurements and Main Results: The primary outcome was respiratory and cardiovascular organ support-free days, assessed on an ordinal scale combining in-hospital death (assigned a value of –1) and days free of organ support through day 21 in survivors. Analyses used a Bayesian cumulative logistic model. Enrollment was closed for operational futility, following external evidence suggesting no benefit with ivermectin in nonhospitalized patients with COVID-19. Among 61 critically ill patients, the median number of organ support-free days was –1, indicating death was the most common vital outcome (interquartile range [IQR], –1 to 17), for the ivermectin group and –1 (IQR, –1 to 17.25) for the control group (adjusted proportional odds ratio [OR], 0.94; 95% credible interval [CrI], 0.40–2.07) and the posterior probability of superiority to control was 44.2%. Among 89 noncritically ill patients, the median number of organ support-free days was 22 (IQR, 18.5–22) for ivermectin and 22 (IQR, 16–22) for control (adjusted proportional OR, 1.04; 95% CrI, 0.48–2.34) and the posterior probability of superiority was 53.7%. Among critically ill patients, hospital survival was 35.1% (13/37) for ivermectin and 37.5% (9/24) for control (adjusted OR, 1.00; 95% CrI, 0.39–2.32), posterior probability of superiority was 50.0%. Among noncritically ill patients, hospital survival was 84.1% (37/44) for ivermectin and 77.8% (35/45) for control (adjusted OR, 1.16; 95% CrI, 0.5–3.07), posterior probability of superiority was 63.3%. Conclusions: For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival.
- 8 May 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (7) , 1546-1562
Open AccessIvermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
Objective: To determine whether ivermectin improves outcomes for critically and noncritically ill hospitalized patients with COVID-19. Design: An ongoing international, multifactorial, adaptive platform, randomized, controlled trial. Setting: Hospitals in Pakistan, India, and Ireland between June 11, 2021, and September 9, 2022. Patients: Critically and noncritically ill patients. Interventions: Randomized to ivermectin or no ivermectin (control). Measurements and Main Results: The primary outcome was respiratory and cardiovascular organ support-free days, assessed on an ordinal scale combining in-hospital death (assigned a value of –1) and days free of organ support through day 21 in survivors. Analyses used a Bayesian cumulative logistic model. Enrollment was closed for operational futility, following external evidence suggesting no benefit with ivermectin in nonhospitalized patients with COVID-19. Among 61 critically ill patients, the median number of organ support-free days was –1, indicating death was the most common vital outcome (interquartile range [IQR], –1 to 17), for the ivermectin group and –1 (IQR, –1 to 17.25) for the control group (adjusted proportional odds ratio [OR], 0.94; 95% credible interval [CrI], 0.40–2.07) and the posterior probability of superiority to control was 44.2%. Among 89 noncritically ill patients, the median number of organ support-free days was 22 (IQR, 18.5–22) for ivermectin and 22 (IQR, 16–22) for control (adjusted proportional OR, 1.04; 95% CrI, 0.48–2.34) and the posterior probability of superiority was 53.7%. Among critically ill patients, hospital survival was 35.1% (13/37) for ivermectin and 37.5% (9/24) for control (adjusted OR, 1.00; 95% CrI, 0.39–2.32), posterior probability of superiority was 50.0%. Among noncritically ill patients, hospital survival was 84.1% (37/44) for ivermectin and 77.8% (35/45) for control (adjusted OR, 1.16; 95% CrI, 0.5–3.07), posterior probability of superiority was 63.3%. Conclusions: For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival.
- Open Access
- 9 July 2025
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 54 (7) , 437-441
Bayesian meta-analysis in the 21st century: Fad or future of evidence synthesis?
Meta-analyses are pivotal in evidence-based medicine. They synthesise findings from multiple studies to inform clinical practice. Traditionally, frequentist statistical methods have dominated this field. However, growing recognition of their limitations in interpreting uncertainty and integrating prior knowledge has led to increased interest in Bayesian methods. We compared the Bayesian and frequentist approaches to meta-analysis, assessed their respective strengths and limitations, and evaluated how each technique influences the interpretation of clinical trial data, particularly when evidence is ambiguous. A narrative review was conducted to understand and compare key aspects of frequentist and Bayesian statistics. Real-world clinical examples were used to illustrate the differences between how each statistical paradigm interprets the same dataset. Frequentist methods were assessed based on null hypothesis testing and P values, while Bayesian methods were evaluated for their use of prior distributions and posterior probabilities. We demonstrated how statistical significance of the obtained result may differ based on whether a frequentist or Bayesian statistical analysis was employed. In most cases, Bayesian methods enabled increased intuitiveness and flexibility of interpretations by incorporating uncertainty and pre-existing evidence. While frequentist methods remain standard for simpler univariate analyses, the Bayesian approach offers a more holistic framework for complex meta-analyses, as it aligns more closely with practical clinical decision-making. This places Bayesian inference a valuable tool in the future of evidence synthesis.
- 9 July 2025
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 54 (7) , 437-441
Open AccessBayesian meta-analysis in the 21st century: Fad or future of evidence synthesis?
Meta-analyses are pivotal in evidence-based medicine. They synthesise findings from multiple studies to inform clinical practice. Traditionally, frequentist statistical methods have dominated this field. However, growing recognition of their limitations in interpreting uncertainty and integrating prior knowledge has led to increased interest in Bayesian methods. We compared the Bayesian and frequentist approaches to meta-analysis, assessed their respective strengths and limitations, and evaluated how each technique influences the interpretation of clinical trial data, particularly when evidence is ambiguous. A narrative review was conducted to understand and compare key aspects of frequentist and Bayesian statistics. Real-world clinical examples were used to illustrate the differences between how each statistical paradigm interprets the same dataset. Frequentist methods were assessed based on null hypothesis testing and P values, while Bayesian methods were evaluated for their use of prior distributions and posterior probabilities. We demonstrated how statistical significance of the obtained result may differ based on whether a frequentist or Bayesian statistical analysis was employed. In most cases, Bayesian methods enabled increased intuitiveness and flexibility of interpretations by incorporating uncertainty and pre-existing evidence. While frequentist methods remain standard for simpler univariate analyses, the Bayesian approach offers a more holistic framework for complex meta-analyses, as it aligns more closely with practical clinical decision-making. This places Bayesian inference a valuable tool in the future of evidence synthesis.
- Open Access
- 20 January 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-3
Forty years on, why are we still publishing extracorporeal carbon dioxide removal feasibility studies?
- 20 January 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-3
Open AccessForty years on, why are we still publishing extracorporeal carbon dioxide removal feasibility studies?
- Open Access
OAH-Net: A Deep Neural Network for Hologram Reconstruction of Off-axis Digital Holographic Microscope
Off-axis digital holographic microscopy is a high-throughput, label-free imaging technology that provides three-dimensional, high-resolution information about samples, particularly useful in large-scale cellular imaging. However, the hologram reconstruction process poses a significant bottleneck for timely data analysis. To address this challenge, we propose a novel reconstruction approach that integrates deep learning with the physical principles of off-axis holography. We initialized part of the network weights based on the physical principle and then fine-tuned them via weakly supersized learning. Our off-axis hologram network (OAH-Net) retrieves phase and amplitude images with errors that fall within the measurement error range attributable to hardware, and its reconstruction speed significantly surpasses the microscope's acquisition rate. Crucially, OAH-Net demonstrates remarkable external generalization capabilities on unseen samples with distinct patterns and can be seamlessly integrated with other models for downstream tasks to achieve end-to-end real-time hologram analysis. This capability further expands off-axis holography's applications in both biological and medical studies.
Open AccessOAH-Net: A Deep Neural Network for Hologram Reconstruction of Off-axis Digital Holographic Microscope
Off-axis digital holographic microscopy is a high-throughput, label-free imaging technology that provides three-dimensional, high-resolution information about samples, particularly useful in large-scale cellular imaging. However, the hologram reconstruction process poses a significant bottleneck for timely data analysis. To address this challenge, we propose a novel reconstruction approach that integrates deep learning with the physical principles of off-axis holography. We initialized part of the network weights based on the physical principle and then fine-tuned them via weakly supersized learning. Our off-axis hologram network (OAH-Net) retrieves phase and amplitude images with errors that fall within the measurement error range attributable to hardware, and its reconstruction speed significantly surpasses the microscope's acquisition rate. Crucially, OAH-Net demonstrates remarkable external generalization capabilities on unseen samples with distinct patterns and can be seamlessly integrated with other models for downstream tasks to achieve end-to-end real-time hologram analysis. This capability further expands off-axis holography's applications in both biological and medical studies.
- 30 August 2023
- Published by Wiley in Respirology
- Vol. 28 (10) , 966-968
Letter from Singapore
- Open Access
- 21 July 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 240, 107728
Virtual patient with temporal evolution for mechanical ventilation trial studies: A stochastic model approach
- 21 July 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 240, 107728
Open AccessVirtual patient with temporal evolution for mechanical ventilation trial studies: A stochastic model approach
- Open Access
- 29 June 2023
- Published by Elsevier in IJID Regions
- Vol. 8, 84-89
Inflammatory phenotypes may be more important than age and comorbidities in predicting clinical outcomes in hospitalised patients with COVID-19
- 29 June 2023
- Published by Elsevier in IJID Regions
- Vol. 8, 84-89
Open AccessInflammatory phenotypes may be more important than age and comorbidities in predicting clinical outcomes in hospitalised patients with COVID-19
- 1 November 2022
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 151 (Pt A) , 106275
Predicting mechanically ventilated patients future respiratory system elastance – A stochastic modelling approach
- 1 November 2022
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 151 (Pt A) , 106275
Predicting mechanically ventilated patients future respiratory system elastance – A stochastic modelling approach
- Open Access
- 10 October 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-3
PEEP, p-values, and pulmonary mechanics; don’t throw the baby out with the bathwater
- 10 October 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-3
Open AccessPEEP, p-values, and pulmonary mechanics; don’t throw the baby out with the bathwater